<DOC>
	<DOC>NCT01546571</DOC>
	<brief_summary>The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.</brief_summary>
	<brief_title>Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirmed Stage IIb, IIc, III melanoma Surgical resection within 90 days of first dosing Persons with positive sentinel nodes must have a complete lymphadenectomy ECOG performance status 0 or 1 Any prior melanoma treatment other than surgery or regional irradiation Diagnosis of noncutaneous melanoma or melanoma with unknown primary origin Use of biologic response modifiers within 60 days of first dosing Subjects with history of other malignancy within past 5 years (with exceptions)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>